Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2019 | Review Article

Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

Authors: Andrea Farolfi, Pietro Ghedini, Stefano Fanti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2019

Abstract

The aim of the review is to highlight articles published in 2017 in the Annals of Nuclear Medicine, an official peer-reviewed journal of the Japanese Society of Nuclear Medicine. Among all published manuscripts during the past year, we conducted a subjective selection of the most relevant topics. Fourteen fascinating articles are included in this review, ranging in topic from preclinical to clinical arenas.

Carrió I, Kinuya S. New section in EJNMMI and Annals of Nuclear Medicine. Ann Nucl Med. 2016;30(9):593.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef

Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015;29(10):877–82.CrossRef

Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31(9):696–702.CrossRef

Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–4.CrossRef

Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31(9):709–17.CrossRef

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94.CrossRef

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2015;56(5):668–74.

Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017;31(7):521–8.CrossRef

10.

Koizumi M, Wagatsuma K, Miyaji N, Murata T, Miwa K, Takiguchi T, et al. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29(2):138–48.CrossRef

11.

Koizumi M, Miyaji N, Murata T, Motegi K, Miwa K, Koyama M, et al. Evaluation of a revised version of computer-assisted diagnosis system, BONENAVI version 2.1.7, for bone scintigraphy in cancer patients. Ann Nucl Med. 2015;29(8):659–65.CrossRef

12.

Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):783–95.CrossRef

13.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.CrossRef

14.

El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recogn. 2009;42(6):1162–71.CrossRef

15.

Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.CrossRef

16.

Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.PubMed

17.

Heryanto Y-D, Hanaoka H, Nakajima T, Yamaguchi A, Tsushima Y. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts. Ann Nucl Med. 2017;31(9):669–77.CrossRef

18.

Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011;17(12):1685–91.CrossRef

19.

Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23(3):175–80.CrossRef

20.

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(10):3375–9.CrossRef

21.

Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, et al. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors. Ann Nucl Med. 2017;31(10):719–25.CrossRef

22.

Takahashi M, Soma T, Mukasa A, Koyama K, Arai T, Momose T. An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using 18F-FDG-PET and 11C-methionine PET. Ann Nucl Med. 2017;31(3):250–9.CrossRef

23.

Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med Off Publ Soc Nucl Med. 1998;39(5):778–85.

24.

de Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med Off Publ Soc Nucl Med. 2005;46 Suppl 1:13S–17S.

25.

Kunikowska J, Pawlak D, Bąk MI, Kos-Kudła B, Mikołajczak R, Królicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31(5):347–56.CrossRef

26.

Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27(7):867–869.CrossRef

27.

Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2013;40(2):213–27.CrossRef

28.

Yamamoto H, Arimura S, Nakanishi A, Shimo Y, Motoi Y, Ishiguro K, et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. Ann Nucl Med. 2017;31(5):407–12.CrossRef

29.

Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med Off Publ Soc Nucl Med. 2009;50(10):1638–45.

30.

Imabayashi E, Soma T, Sone D, Tsukamoto T, Kimura Y, Sato N, et al. Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer’s disease using brain perfusion SPECT. Ann Nucl Med. 2017;31(7):536–43.CrossRef

31.

Imabayashi E, Yokoyama K, Tsukamoto T, Sone D, Sumida K, Kimura Y, et al. The cingulate island sign within early Alzheimer’s disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer’s disease from dementia with Lewy bodies. EJNMMI Res. 2016;6(1):67.CrossRef

32.

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2003;61(9):1115–7.CrossRef

33.

Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 1939. 2011;142(11):1243–51.CrossRef

34.

Schauwecker DS. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol. 1992;158(1):9–18.CrossRef

35.

Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dento Maxillo Facial Radiol. 2006;35(4):236–43.CrossRef

36.

Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2009;67(5 Suppl):75–84.CrossRef

37.

O’Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2009;67(7):1363–72.CrossRef

38.

Thomas C, Spanidis M, Engel C, Roos FC, Frees S, Neisius A, et al. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). Clin Oral Investig. 2016;20(4):753–8.CrossRef

39.

Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med. 2011;36(1):17–20.CrossRef

40.

Watanabe S, Nakajima K, Mizokami A, Yaegashi H, Noguchi N, Kawashiri S, et al. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. Ann Nucl Med. 2017;31(3):201–10.CrossRef

41.

Troost EGC, Laverman P, Philippens MEP, Lok J, van der Kogel AJ, Oyen WJG, et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 2008;35(10):1803–11.CrossRef

42.

Masaki Y, Shimizu Y, Yoshioka T, Tanaka Y, Nishijima K-I, Zhao S, et al. The accumulation mechanism of the hypoxia imaging probe ‘FMISO’ by imaging mass spectrometry: possible involvement of low-molecular metabolites. Sci Rep. 2015;5:16802.CrossRef

43.

Masaki Y, Shimizu Y, Yoshioka T, Nishijima K-I, Zhao S, Higashino K, et al. FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state. Ann Nucl Med. 2017;31(8):596–604.CrossRef

44.

Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2009;67(7–8 Suppl):S348–50.

45.

Watabe T, Hanaoka K, Naka S, Kanai Y, Ikeda H, Aoki M, et al. Practical calculation method to estimate the absolute boron concentration in tissues using 18F-FBPA PET. Ann Nucl Med. 2017;31(6):481–5.CrossRef

46.

Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4(1):70.CrossRef

47.

Lasnon C, Salomon T, Desmonts C, Dô P, Oulkhouir Y, Madelaine J, et al. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Ann Nucl Med. 2017;31(2):125–34.CrossRef

Title: Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine
Authors: Andrea Farolfi
Pietro Ghedini
Stefano Fanti
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4169-y

At a glance: The STEP trials

Springer Medicine

Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study

Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy

Correction to: Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Alan F. Weissman (Ed). Top Score for the Radiology Boards. Q&A for the Core and Certifying Exams